Pharmaceutical forum is open to any pharmacist who is engaged with industrial practice. Its a platform to share and update your industry related knowledge and skills. Eg: DCGI notifications, D&C Act, Formulation methods and Policy initiatives.
Forum rules: Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
Mature and active TGF-β ligands are formed by much larger precursor molecules. The active precursors include two of the carboxy-terminal mature domains in either homo- or heterodimer conformations. The amino-terminal signal peptide is cleaved at a conserved Arg-X-Arg-Arg site when translocated into the lumen of the rough endoplasmic reticulum, leaving the carboxy-terminal TGF-β superfamily mature monomer polypeptide. For TGF-β superfamily members, the mature domain is related to a latency associated peptide (LAP) which helps the protein move toward sites of activation or storage.